Keywords
Show more Keywords
Table of contents
  1. 1. Clinical Trial
  2. 2. Routine Documentation
  3. 3. Registry/Cohort Study
  4. 4. Quality Assurance
  5. 5. Data Standard
  6. 6. Patient-Reported Outcome
  7. 7. Medical Specialty
Selected data models

You must log in to select data models for download or further analysis.

20594 Search results.

Eligibility Knee Osteoarthritis NCT02294864

- 4/24/19 - 1 form, 2 itemgroups, 11 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
A Controlled Comparison of Pulsed Radiofrequency Vs Physical Therapy on Treating Chronic Knee Osteoarthritis; ODM derived from: https://clinicaltrials.gov/show/NCT02294864

Eligibility Knee Osteoarthritis NCT02254473

- 4/24/19 - 1 form, 2 itemgroups, 18 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Evaluating the Efficacy of Lateral Heel Wedges of Osteoarthritis of the Knee; ODM derived from: https://clinicaltrials.gov/show/NCT02254473

Eligibility Knee Osteoarthritis NCT02205814

- 4/24/19 - 1 form, 2 itemgroups, 15 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Fasitibant Intra-articular Injection in Patients With Symptomatic Osteoarthritis of the Knee; ODM derived from: https://clinicaltrials.gov/show/NCT02205814

Eligibility Knee Osteoarthritis NCT02104596

- 4/24/19 - 1 form, 2 itemgroups, 14 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Intraarticular Xylitol Injections for Knee Osteoarthritis; ODM derived from: https://clinicaltrials.gov/show/NCT02104596

Eligibility Knee Osteoarthritis NCT02083861

- 4/23/19 - 1 form, 2 itemgroups, 17 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Wearable LITUS Device for Osteoarthritis of the Knee: a Randomized Double-Blind Placebo-Controlled Trial; ODM derived from: https://clinicaltrials.gov/show/NCT02083861

Eligibility Knee Osteoarthritis NCT02067208

- 4/23/19 - 1 form, 2 itemgroups, 11 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Wedged Insoles for Management of Knee Osteoarthritis; ODM derived from: https://clinicaltrials.gov/show/NCT02067208

Eligibility Knee Osteoarthritis NCT02019108

- 4/23/19 - 1 form, 2 itemgroups, 11 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Gait Modification Treatment for Knee Osteoarthritis; ODM derived from: https://clinicaltrials.gov/show/NCT02019108

The Effect of Particle Size on the Pharmacokinetics of a Single mg Dose of GW856553 NCT00517543 - Screen - Date of Visit; Demography, 12-Lead ECG; Vital Signs; Eligibility Question; Subject Identification; Electronically Transferred Lab Data

- 4/23/19 - 1 form, 9 itemgroups, 37 items, 1 language
Itemgroups: Inform Screening, Subject number, Date of Visit/ Assessment, Demography, 12-Lead ECG, Vital Signs, Eligibility Question, Subject idetification, Electronically Transferred Lab Data
Study ID: 109385 Clinical Study ID: 109385 Study Title: A Randomized, Open Label, 4 Period Crossover Study in Healthy Subjects to Determine the Effect of Particle Size on the Pharmacokinetics of a Single mg Dose of GW856553 Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00517543 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 1 Study Recruitment Status: Completed Generic Name: GW856553 Trade Name: N/A Study Indication: Chronic Obstructive Pulmonary Disease (COPD), Rheumatoid Arthritis, Atherosclerosis

The Effect of Particle Size on the Pharmacokinetics of a Single mg Dose of GW856553 NCT00517543 - Period 1 - Randomisation Number; 12-Lead ECG; Vital Signs; Pharmacokinetics Blood GW856553; Electronically Transferred Lab Data; Investigational Product

- 4/23/19 - 1 form, 17 itemgroups, 106 items, 1 language
Itemgroups: Randomisation Number, 12 Lead ECG - Dosing Date and Time, 12-Lead ECG - Pre-dose-measurement 1 (of 3) at least 5 minutes apart, 12-Lead ECG - Pre-dose-measurement 2 (of 3) at least 5 minutes apart , 12-Lead ECG - Pre-dose-measurement 3 (of 3) at least 5 minutes apart , 12-Lead ECG - 30 mins, 12-Lead ECG - 1 hr, 12-Lead ECG - 24 hr , Vital Signs, Vital Signs - Pre dose, Vital Signs - 30 mins, Vital Signs - 24 hrs, Pharmacokinetics Blood - GW856553, Electronically Transferred Lab Data - Pre dose, Electronically Transferred Lab Data - 24 hrs (Day 2), Electronically Transferred Lab Data - 72 hrs (Day 4) , Investigational Product
Study ID: 109385 Clinical Study ID: 109385 Study Title: A Randomized, Open Label, 4 Period Crossover Study in Healthy Subjects to Determine the Effect of Particle Size on the Pharmacokinetics of a Single mg Dose of GW856553 Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00517543 Sponsor: GlaxoSmithKline Phase: Phase 1 Study Recruitment Status: Completed Generic Name: GW856553 Trade Name: N/A Study Indication: Chronic Obstructive Pulmonary Disease (COPD), Rheumatoid Arthritis, Atherosclerosis

The Effect of Particle Size on the Pharmacokinetics of a Single mg Dose of GW856553 NCT00517543 - Period 2 - 12-Lead ECG; Vital Signs; Pharmacokinetics Blood GW856553; Electronically Transferred Lab Data; Investigational Product

- 4/23/19 - 1 form, 8 itemgroups, 50 items, 1 language
Itemgroups: Administrative Data, 12-Lead ECG, Vital Signs, Pharmacokinetics Blood - GW856553, Electronically Transferred Lab Data - Pre dose, Electronically Transferred Lab Data - 24 hrs (Day 2), Electronically Transferred Lab Data - 72 hrs (Day 4) , Investigational Product
Study ID: 109385 Clinical Study ID: 109385 Study Title: A Randomized, Open Label, 4 Period Crossover Study in Healthy Subjects to Determine the Effect of Particle Size on the Pharmacokinetics of a Single mg Dose of GW856553 Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00517543 Sponsor: GlaxoSmithKline Phase: Phase 1 Study Recruitment Status: Completed Generic Name: GW856553 Trade Name: N/A Study Indication: Chronic Obstructive Pulmonary Disease (COPD), Rheumatoid Arthritis, Atherosclerosis

The Effect of Particle Size on the Pharmacokinetics of a Single mg Dose of GW856553 NCT00517543 - Period 3 - 12-Lead ECG; Vital Signs; Pharmacokinetics Blood GW856553; Electronically Transferred Lab Data; Investigational Product

- 4/23/19 - 1 form, 8 itemgroups, 50 items, 1 language
Itemgroups: Administrative Data, 12-Lead ECG, Vital Signs, Pharmacokinetics Blood - GW856553, Electronically Transferred Lab Data - Pre dose, Electronically Transferred Lab Data - 24 hrs (Day 2), Electronically Transferred Lab Data - 72 hrs (Day 4) , Investigational Product
Study ID: 109385 Clinical Study ID: 109385 Study Title: A Randomized, Open Label, 4 Period Crossover Study in Healthy Subjects to Determine the Effect of Particle Size on the Pharmacokinetics of a Single mg Dose of GW856553 Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00517543 Sponsor: GlaxoSmithKline Phase: Phase 1 Study Recruitment Status: Completed Generic Name: GW856553 Trade Name: N/A Study Indication: Chronic Obstructive Pulmonary Disease (COPD), Rheumatoid Arthritis, Atherosclerosis

The Effect of Particle Size on the Pharmacokinetics of a Single mg Dose of GW856553 NCT00517543 - Period 4 - 12-Lead ECG; Vital Signs; Pharmacokinetics Blood GW856553; Electronically Transferred Lab Data; Investigational Product

- 4/23/19 - 1 form, 8 itemgroups, 50 items, 1 language
Itemgroups: Administrative Data, 12-Lead ECG, Vital Signs, Pharmacokinetics Blood - GW856553, Electronically Transferred Lab Data - Pre dose, Electronically Transferred Lab Data - 24 hrs (Day 2), Electronically Transferred Lab Data - 72 hrs (Day 4) , Investigational Product
Study ID: 109385 Clinical Study ID: 109385 Study Title: A Randomized, Open Label, 4 Period Crossover Study in Healthy Subjects to Determine the Effect of Particle Size on the Pharmacokinetics of a Single mg Dose of GW856553 Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00517543 Sponsor: GlaxoSmithKline Phase: Phase 1 Study Recruitment Status: Completed Generic Name: GW856553 Trade Name: N/A Study Indication: Chronic Obstructive Pulmonary Disease (COPD), Rheumatoid Arthritis, Atherosclerosis